Weighted genotypic resistance scores represent a step towards excellence in the interpretation of HIV type-1 (HIV-1) resistance to antiretroviral drugs. They can predict phenotypic resistance and clinical response better than any other unweighted score. With the addition of mutations associated with an increased response and the refinement of the initial weighted score in a different dataset of individuals, the updated tipranavir score will doubtlessly be a thorough and user-friendly tool that narrows the gap existing between basic science in HIV-1 resistance to antiretrovirals and daily point-of-care clinical practice. The accuracy of the design and the steps used in its validation represent a milestone in HIV-1 resistance knowledge that should also be applied to other antiretroviral drugs in the future.
References
1.
HirschM.S., GunthardH.F., SchapiroJ.M.Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society–USA panel.Clin Infect Dis2008; 47: 266–285.
2.
Panel on Antiretroviral Guidelines for Adults and Adolescents.Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. December 1, 2009; 1–161. (Accessed 3 December 2009.) Available from http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf.
3.
HoggR.S., BangsbergD.R., LimaV.D.Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART.PLoS Med2006; 3: e356.
4.
ShaferR.W., SchapiroJ.M.HIV-1 drug resistance mutations: an updated framework for the second decade of HAART.AIDS Rev2008; 10: 67–84.
5.
de MendozaC., AntaL., GarciaF.HIV-1 Genotypic drug resistance interpretation rules – 2009 Spanish Guidelines.AIDS Rev2009; 11: 39–51.
6.
LlibreJ.M., SchapiroJ.M., ClotetB.Clinical implications of genotypic resistance to the newer antiretroviral drugs in HIV-1-infected patients with virological failure.Clin Infect Dis2010; 50: 872–881.
7.
ShaferR.W., RheeS.Y., BennettD.E.Consensus drug resistance mutations for epidemiological surveillance: basic principles and potential controversies.Antivir Ther2008; 13 Suppl 2: 59–68.
8.
ShaferR.W.Rationale and uses of a public HIV drug-resistance database.J Infect Dis2006; 194 Suppl 1: S51–S58.
9.
JohnsonV.A., Brun-VezinetF., ClotetB.Update of the drug resistance mutations in HIV-1: December 2009.Top HIV Med2009; 17: 138–145.
10.
BenhamidaJ., ChappeyC., CoakleyE., ParkinN.HIV-1 genotype algorithms for prediction of etravirine susceptibility: novel mutations and weighting factors identified through correlations to phenotype.Antivir Ther2008; 13 Suppl 3: A142.
11.
VingerhoetsJ., PeetersM., AzijnH.An update of the list of NNRTI mutations associated with decreased virologic response to etravirine (ETR): multivariate analyses on the pooled DUET-1 and DUET-2 clinical trial data.The XVII International Drug Resistance Workshop. 10–14 June 2008, Sitges, Spain. Abstract 24.
12.
SchererJ., BoucherC., BaxterJ.D., SchapiroJ.M., KohlbrennerV.M., HallD.B.Improving the prediction of virologic response to tipranavir: the development of a tipranavir weighted score.11th European AIDS Conference. 24–27 October 2007. Madrid, Spain. Abstract P3.4/07.
13.
BaxterJ.D., SchapiroJ.M., BoucherC.A.Genotypic changes in human immunodeficiency virus type 1 protease associated with reduced susceptibility and virologic response to the protease inhibitor tipranavir.J Virol2006; 80: 10794–10801.
14.
DoyonL., TremblayS., BourgonL., WardropE., CordingleyM.G.Selection and characterization of HIV-1 showing reduced susceptibility to the non-peptidic protease inhibitor tipranavir.Antiviral Res2005; 68: 27–35.
15.
Stanford University HIV Drug Resistance Database. Version 6.0.8. (Accessed 4 June 2010.) Available from http://hivdb.stanford.edu/.
16.
ParkinN., ChappeyC.Protease mutations associated with higher or lower than expected tipranavir (TPV) susceptibility based on the TPV mutation score.13th Conference on Retroviruses and Opportunistic Infections. 5–8 February 2006, Denver, CO, USA. Abstract 637.
17.
NaegerL.K., StrubleK.A.Food and Drug Administration analysis of tipranavir clinical resistance in HIV-1-infected treatment-experienced patients.AIDS2007; 21: 179–185.
SchererJ., BoucherC.A., BaxterJ., SchapiroJ.M., KohlbrennerV.M., HallD.B.Improving the prediction of virologic response to tipranavir: the development of a tipranavir weighted mutation score.6th European HIV Drug Resistance Workshop. 26–28 March 2008, Budapest, Hungary. Abstract 94.
20.
SchapiroJ.M., SchererJ., BoucherC.A.Improving the prediction of virologic response to tipranavir: the development and validation of a tipranavir-weighted mutation score.Antivir Ther2010; doi: 10.3851/IMP1670.
21.
SchererJ., SchapiroJ.M., MaggioloF.Improved tipranavir weighted score predicts virologic response in diverse treatment-experienced patient populations.7th European HIV Drug Resistance Workshop. 25–28 March 2009, Stockholm, Sweden. Abstract 94.
